Seyed Mehdi Kalantar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seyed Mehdi Kalantar has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Fateme Sefid
Department of Molecular Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd 8916978477, Iran
4 shared publications - Mohammad Hasan Sheikhha
Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publications - Mojtaba Movahedinia
Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publications - Nasrin Ghasemi
Abortion Research Center, Reproductive Sciences Institute, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publications Noorodin Karami
Abortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publicationsSeyed Hamidreza Mirabutalebi
Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 shared publications
Latest Publications
- 6 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1907
Clinical and genetic characterization of three Iranian patients carrying the CLCN1 p.Pro452Leu variant
- 6 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1907
Clinical and genetic characterization of three Iranian patients carrying the CLCN1 p.Pro452Leu variant
- 17 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1755
Co-existence of CLCN1 and DNM2 variants in a phenotype overlapping myotonia and myopathy
- 17 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1755
Co-existence of CLCN1 and DNM2 variants in a phenotype overlapping myotonia and myopathy
- 16 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1729
A novel de novo variant of CDKL5 in an Iranian child with infantile-onset refractory epilepsy
Background Epilepsy is defined as a long-term brain disease with recurrent and spontaneous seizures that often begin in childhood and encompass a wide range of etiologies, including genetic factors. This study aimed to identify and characterize the genetic cause underlying developmental delay and refractory epilepsy in an Iranian patient. Methods We performed a prospective evaluation of an Iranian girl presenting with developmental delay, refractory seizures, and hypotonia. The case was referred to the Genetic Research Center, Meybod,, Iran. Whole exome sequencing and Sanger sequencing were performed to identify the disease-causing variant and validate it, respectively. Also, bioinformatic analyses were used to evaluate the predicted pathogenicity and structural consequences of the variants. Results A novel de novo frameshift variant in CDKL5 gene (c.1037_1038delTCinsCAGATCTAA, p.Ile346Thrfs*14) was identified and classified as pathogenic based on ACMG criteria. The variant is predicted to engender a premature stop codon, leading to extensive shortening of the protein and loss of essential functional domains. Additionally, Valproate-Lamotrigine combination therapy resulted in significant clinical effects, such as a considerable reduction in the number of seizures. Conclusion The present study can expand the mutational spectrum of CDKL5 and highlight the clinical advantage of sequencing-based genetic testing for early diagnosis and personalized therapeutic management of refractory epilepsy.
- 16 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1729
A novel de novo variant of CDKL5 in an Iranian child with infantile-onset refractory epilepsy
Background Epilepsy is defined as a long-term brain disease with recurrent and spontaneous seizures that often begin in childhood and encompass a wide range of etiologies, including genetic factors. This study aimed to identify and characterize the genetic cause underlying developmental delay and refractory epilepsy in an Iranian patient. Methods We performed a prospective evaluation of an Iranian girl presenting with developmental delay, refractory seizures, and hypotonia. The case was referred to the Genetic Research Center, Meybod,, Iran. Whole exome sequencing and Sanger sequencing were performed to identify the disease-causing variant and validate it, respectively. Also, bioinformatic analyses were used to evaluate the predicted pathogenicity and structural consequences of the variants. Results A novel de novo frameshift variant in CDKL5 gene (c.1037_1038delTCinsCAGATCTAA, p.Ile346Thrfs*14) was identified and classified as pathogenic based on ACMG criteria. The variant is predicted to engender a premature stop codon, leading to extensive shortening of the protein and loss of essential functional domains. Additionally, Valproate-Lamotrigine combination therapy resulted in significant clinical effects, such as a considerable reduction in the number of seizures. Conclusion The present study can expand the mutational spectrum of CDKL5 and highlight the clinical advantage of sequencing-based genetic testing for early diagnosis and personalized therapeutic management of refractory epilepsy.
- Open Access
- 13 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7230
Whole-Genome Sequencing Identifies Potentially Causative Variants in SOX30, AKAP4, and RNF220 in Non-Obstructive Azoospermia
More than 70% of non-obstructive azoospermia (NOA) cases remain idiopathic, and the underlying genetic causes need to be investigated. In this study, we aimed to identify genes and variants associated with the etiology of NOA. Two NOA patients from consanguineous families, with normal karyotypes and no Y-chromosome microdeletions, were selected for whole-genome sequencing (WGS). Candidate variants were validated by Sanger sequencing. Structural protein modeling and assessment of mutation-induced changes in molecular interactions were performed using SWISS-MODEL and AlphaFold. We identified a candidate homozygous missense variant (c.899C>T, p.(Ser300Phe); rs375931805) in SOX30 in one patient; this transcription factor is highly expressed in the testis. In the second patient, a homozygous missense variant (c.1472C>T, p.(Thr491Met); rs746902232) in RNF220 and a hemizygous missense variant (c.2354A>G, p.(Gln785Arg) in the X-linked AKAP4 gene were simultaneously detected. Previous studies have shown that SOX30 knockout in mice leads to meiosis I arrest and impaired spermiogenesis. AKAP4 is exclusively expressed in the testis, and missense variants have been reported in different forms of male infertility. The co-occurrence of variants in AKAP4 and RNF220 may suggest an oligogenic etiology of NOA and contribute to the phenotypic variability associated with AKAP4 variants.
- 13 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7230
Open AccessWhole-Genome Sequencing Identifies Potentially Causative Variants in SOX30, AKAP4, and RNF220 in Non-Obstructive Azoospermia
More than 70% of non-obstructive azoospermia (NOA) cases remain idiopathic, and the underlying genetic causes need to be investigated. In this study, we aimed to identify genes and variants associated with the etiology of NOA. Two NOA patients from consanguineous families, with normal karyotypes and no Y-chromosome microdeletions, were selected for whole-genome sequencing (WGS). Candidate variants were validated by Sanger sequencing. Structural protein modeling and assessment of mutation-induced changes in molecular interactions were performed using SWISS-MODEL and AlphaFold. We identified a candidate homozygous missense variant (c.899C>T, p.(Ser300Phe); rs375931805) in SOX30 in one patient; this transcription factor is highly expressed in the testis. In the second patient, a homozygous missense variant (c.1472C>T, p.(Thr491Met); rs746902232) in RNF220 and a hemizygous missense variant (c.2354A>G, p.(Gln785Arg) in the X-linked AKAP4 gene were simultaneously detected. Previous studies have shown that SOX30 knockout in mice leads to meiosis I arrest and impaired spermiogenesis. AKAP4 is exclusively expressed in the testis, and missense variants have been reported in different forms of male infertility. The co-occurrence of variants in AKAP4 and RNF220 may suggest an oligogenic etiology of NOA and contribute to the phenotypic variability associated with AKAP4 variants.
- Open Access
- 11 February 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (2) , e70221
Prevalence of HSV‐1/HSV‐2 and CMV Infections in Infertile Men and Their Impact on Sperm Parameters: A Cross‐Sectional Study in Iran
Background and Aims: Viral infections are significant contributors to infertility. This study aimed to determine the prevalence of Herpes Simplex Virus 1 and 2 (HSV‐1/HSV‐2) and cytomegalovirus (CMV) infections in men with infertility, compared to a control group of fertile men.Methods: A cross‐sectional study was conducted with seminal fluid samples from 100 fertile and 100 infertile men, aged 20–40 years, referred to Yazd Infertility Center. DNA extraction was done using the AmpliSens kit, and the presence of CMV and HSV‐1/HSV‐2 was determined via real‐time PCR. Sperm parameters (count, quick & slow, motility, morphology, and volume) were also assessed and compared to the control group.Results: CMV infection was found in 16% of fertile and 10% of infertile men. HSV‐1/HSV‐2 prevalence was significantly higher in infertile men (32%) compared to fertile men (8%). Abnormal sperm count was significantly associated with HSV status (p = 0.001), as was abnormal morphology (p = 0.021), while abnormal quick & slow, motility and volume showed no significant association. Data analysis indicated no correlation between sperm parameters—including sperm quick & slow, motility, count, morphology, and semen volume—and CMV infection.Conclusion: HSV infection is linked to sperm‐specific parameters, particularly count and morphology. These findings enhance our understanding of viral‐induced male infertility and underscore the need for targeted approaches to manage HSV‐1/HSV‐2‐related infertility.
- 11 February 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (2) , e70221
Open AccessPrevalence of HSV‐1/HSV‐2 and CMV Infections in Infertile Men and Their Impact on Sperm Parameters: A Cross‐Sectional Study in Iran
Background and Aims: Viral infections are significant contributors to infertility. This study aimed to determine the prevalence of Herpes Simplex Virus 1 and 2 (HSV‐1/HSV‐2) and cytomegalovirus (CMV) infections in men with infertility, compared to a control group of fertile men.Methods: A cross‐sectional study was conducted with seminal fluid samples from 100 fertile and 100 infertile men, aged 20–40 years, referred to Yazd Infertility Center. DNA extraction was done using the AmpliSens kit, and the presence of CMV and HSV‐1/HSV‐2 was determined via real‐time PCR. Sperm parameters (count, quick & slow, motility, morphology, and volume) were also assessed and compared to the control group.Results: CMV infection was found in 16% of fertile and 10% of infertile men. HSV‐1/HSV‐2 prevalence was significantly higher in infertile men (32%) compared to fertile men (8%). Abnormal sperm count was significantly associated with HSV status (p = 0.001), as was abnormal morphology (p = 0.021), while abnormal quick & slow, motility and volume showed no significant association. Data analysis indicated no correlation between sperm parameters—including sperm quick & slow, motility, count, morphology, and semen volume—and CMV infection.Conclusion: HSV infection is linked to sperm‐specific parameters, particularly count and morphology. These findings enhance our understanding of viral‐induced male infertility and underscore the need for targeted approaches to manage HSV‐1/HSV‐2‐related infertility.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Genetic Characterization of MODY in Iranian Families Using Multigenerational‐Based Whole‐Exome Sequencing Approach
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Open AccessGenetic Characterization of MODY in Iranian Families Using Multigenerational‐Based Whole‐Exome Sequencing Approach
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.
- Open Access
- 31 October 2024
- Published by Biomedpress in Biomedical Research and Therapy
- Vol. 11 (10) , 6838-6844
Methylation of HPV-16 and HPV-18 E6 promoter CpG sites in women with abnormal pap smears
Introduction: HPV-16 and HPV-18 account for around 70% of cases of invasive cervical cancer worldwide. These are highly pathogenic and high-risk genotypes. The most prevalent sexually transmitted disease is human high-risk papillomavirus (HR-HPV), which can infect anyone who engages in sexual activity at any time in their life. To evaluate the possibility that the virus causes malignant lesions in infected women with high-risk HPV types who have normal and abnormal Pap smears, the current study examined the methylation pattern of CpG islands in the oncogene promoter of high-risk HPV E6. Methods: Forty-eight Pap smears were collected from women referred to Shahid Sadoughi Hospital in Yazd for this case-control study. The Sinaclon kit was used for DNA extraction. PCR amplification with specific primers allowed the identification of HPV-16 and HPV-18 types. The bisulfite modification method, based on the EpiTect Bisulfite Conversion Kit, was then used to identify methylation in the E6 gene. Version 22 of the SPSS program was used to collect the data, and the corresponding statistical tests were used for analysis. Results: In this study, methylation at position 506 in the HPV-16 E6 gene was detected in 10.4% (n = 5/48) of cases; however, methylation in the 1985 region for the E6 promoter of HPV-18 was 20.8% (n = 10/48). Comparison of the methylation rate in the HPV-18 nucleotide 1985 in normal and abnormal Pap smear samples showed that the methylation rate in normal and abnormal samples was 55.8% and 44.2%, respectively. There was no significant difference between the frequency of HPV-18 and HPV-16 DNA methylation in all selected CpG nucleotide regions (P ≥ 0.05). Conclusion: Our results indicate that the methylation change in the E6 gene promoter was not involved in the development of infection with HPV-16 and HPV-18 types in the study population.
- 31 October 2024
- Published by Biomedpress in Biomedical Research and Therapy
- Vol. 11 (10) , 6838-6844
Open AccessMethylation of HPV-16 and HPV-18 E6 promoter CpG sites in women with abnormal pap smears
Introduction: HPV-16 and HPV-18 account for around 70% of cases of invasive cervical cancer worldwide. These are highly pathogenic and high-risk genotypes. The most prevalent sexually transmitted disease is human high-risk papillomavirus (HR-HPV), which can infect anyone who engages in sexual activity at any time in their life. To evaluate the possibility that the virus causes malignant lesions in infected women with high-risk HPV types who have normal and abnormal Pap smears, the current study examined the methylation pattern of CpG islands in the oncogene promoter of high-risk HPV E6. Methods: Forty-eight Pap smears were collected from women referred to Shahid Sadoughi Hospital in Yazd for this case-control study. The Sinaclon kit was used for DNA extraction. PCR amplification with specific primers allowed the identification of HPV-16 and HPV-18 types. The bisulfite modification method, based on the EpiTect Bisulfite Conversion Kit, was then used to identify methylation in the E6 gene. Version 22 of the SPSS program was used to collect the data, and the corresponding statistical tests were used for analysis. Results: In this study, methylation at position 506 in the HPV-16 E6 gene was detected in 10.4% (n = 5/48) of cases; however, methylation in the 1985 region for the E6 promoter of HPV-18 was 20.8% (n = 10/48). Comparison of the methylation rate in the HPV-18 nucleotide 1985 in normal and abnormal Pap smear samples showed that the methylation rate in normal and abnormal samples was 55.8% and 44.2%, respectively. There was no significant difference between the frequency of HPV-18 and HPV-16 DNA methylation in all selected CpG nucleotide regions (P ≥ 0.05). Conclusion: Our results indicate that the methylation change in the E6 gene promoter was not involved in the development of infection with HPV-16 and HPV-18 types in the study population.
- Open Access
- 12 May 2024
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 22 (3) , 177-190
Comparing the advantages, disadvantages and diagnostic power of different non-invasive pre-implantation genetic testing: A literature review
To improve embryo transfer success and increase the chances of live birth in assisted reproductive methods, there is a growing demand for the use of pre-implantation genetic testing (PGT). However, the invasive approaches used in PGT have led to in vitro fertilization failure and abortions, increasing anxiety levels for parents. To address this, non-invasive PGT methods have been introduced, such as the detection of DNA in blastocoel fluid of blastocysts and spent culture media (SCM). These methods have proven to be minimally invasive and effective in detecting aneuploidy in the chromosomes of human embryos. This review aims to explore the different approaches to pre-implantation diagnosis, including invasive and non-invasive methods, with a particular focus on non-invasive PGT (niPGT). The search strategy involved gathering data from scientific databases such as PubMed, Google Scholar, and Science Direct using relevant keywords. The search was conducted until January 2023. In total, 22 studies have successfully reported the detection and amplification of cell-free DNA in the embryonic SCM. It is important to note that niPGT has some limitations, which include differences in indicators such as cell-free DNA amplification rate, concordance, level of maternal DNA contamination, sensitivity, and specificity between SCM samples and biopsied cells. Therefore, more extensive and detailed research is needed to fully understand niPGT’s potential for clinical applications. Key words: Spent culture media, Non-invasive pre-implantation genetic testing, Biopsy methods, Cell-free embryonic DNA.
- 12 May 2024
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 22 (3) , 177-190
Open AccessComparing the advantages, disadvantages and diagnostic power of different non-invasive pre-implantation genetic testing: A literature review
To improve embryo transfer success and increase the chances of live birth in assisted reproductive methods, there is a growing demand for the use of pre-implantation genetic testing (PGT). However, the invasive approaches used in PGT have led to in vitro fertilization failure and abortions, increasing anxiety levels for parents. To address this, non-invasive PGT methods have been introduced, such as the detection of DNA in blastocoel fluid of blastocysts and spent culture media (SCM). These methods have proven to be minimally invasive and effective in detecting aneuploidy in the chromosomes of human embryos. This review aims to explore the different approaches to pre-implantation diagnosis, including invasive and non-invasive methods, with a particular focus on non-invasive PGT (niPGT). The search strategy involved gathering data from scientific databases such as PubMed, Google Scholar, and Science Direct using relevant keywords. The search was conducted until January 2023. In total, 22 studies have successfully reported the detection and amplification of cell-free DNA in the embryonic SCM. It is important to note that niPGT has some limitations, which include differences in indicators such as cell-free DNA amplification rate, concordance, level of maternal DNA contamination, sensitivity, and specificity between SCM samples and biopsied cells. Therefore, more extensive and detailed research is needed to fully understand niPGT’s potential for clinical applications. Key words: Spent culture media, Non-invasive pre-implantation genetic testing, Biopsy methods, Cell-free embryonic DNA.
- Open Access
- 26 February 2024
- Published by Brieflands in Jentashapir Journal of Cellular and Molecular Biology
- Vol. 15 (1)
Exploring the Influence of Sialic Acid on Drug Resistance in Glioma: A Focus on ABCB1 and ABCC1 Transporter Genes Expression
Background: Glioma, the predominant type of tumor in the central nervous system (CNS), is commonly treated with temozolomide chemotherapy, radiation therapy, and surgery. However, resistance to chemotherapy can sometimes lead to treatment failure and cancer recurrence. To improve treatment strategies for glioma, it is important to understand the tumor microenvironment (TME) and the molecular aspects that contribute to drug resistance. Objectives: The present study aimed to investigate the effects of sialic acid on drug resistance development in temozolomide-treated cells by analyzing the expression patterns of ABCB1 and ABCC1 genes, known for their role in drug resistance mechanisms. Methods: This study examined the effects of temozolomide, sialic acid, and the combination of both on cell viability and apoptosis. IC50 and EC50 values were used to measure treatment effectiveness, and the expression of ABCB1 and ABCC1 genes was assessed by real-time PCR in different treatment groups. Results: Temozolomide and sialic acid both had effects on cell viability, morphology, and the expression of ABCB1 and ABCC1 genes. These alterations may be associated with the development of drug resistance in cancer cells, providing insight into the underlying mechanisms. Conclusions: The study suggests that sialic acid promotes cancer progression and reduces the effectiveness of anticancer drugs. Therefore, targeting sialic acid or its production and using combination drugs could be a promising strategy to counter its negative impact on treatment outcomes.
- 26 February 2024
- Published by Brieflands in Jentashapir Journal of Cellular and Molecular Biology
- Vol. 15 (1)
Open AccessExploring the Influence of Sialic Acid on Drug Resistance in Glioma: A Focus on ABCB1 and ABCC1 Transporter Genes Expression
Background: Glioma, the predominant type of tumor in the central nervous system (CNS), is commonly treated with temozolomide chemotherapy, radiation therapy, and surgery. However, resistance to chemotherapy can sometimes lead to treatment failure and cancer recurrence. To improve treatment strategies for glioma, it is important to understand the tumor microenvironment (TME) and the molecular aspects that contribute to drug resistance. Objectives: The present study aimed to investigate the effects of sialic acid on drug resistance development in temozolomide-treated cells by analyzing the expression patterns of ABCB1 and ABCC1 genes, known for their role in drug resistance mechanisms. Methods: This study examined the effects of temozolomide, sialic acid, and the combination of both on cell viability and apoptosis. IC50 and EC50 values were used to measure treatment effectiveness, and the expression of ABCB1 and ABCC1 genes was assessed by real-time PCR in different treatment groups. Results: Temozolomide and sialic acid both had effects on cell viability, morphology, and the expression of ABCB1 and ABCC1 genes. These alterations may be associated with the development of drug resistance in cancer cells, providing insight into the underlying mechanisms. Conclusions: The study suggests that sialic acid promotes cancer progression and reduces the effectiveness of anticancer drugs. Therefore, targeting sialic acid or its production and using combination drugs could be a promising strategy to counter its negative impact on treatment outcomes.
- Open Access
- 1 January 2024
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 28 (3) , 405-409
Comparison of SPAG11A gene expression in infertile men with grade 1 and 2 varicocele before and after treatment
Objective: Sperm Associated Antigen 11A ( SPAG11A ) protein is a family of the epididymis-specific secretory proteins implicated in sperm maturation and function. Varicocele might cause pathophysiological difficulties in the testis and epididymis, with a harmful effect on the environment for spermatogenesis and sperm maturation. The aim of this study was to evaluate the expression level of the SPAG11A gene and sperm parameters in infertile men with grade 1 and 2 varicocele before and after treatment. Methods: Semen specimens were collected from 20 infertile men with varicocele pre-and post-treatment and 10 healthy volunteers. Semen analysis was conducted according to world health organization guidelines. Real time PCR (qRT-PCR) reaction was applied for determination of SPAG11A mRNA expression. Results: The results showed that there was a significant difference between the concentration and normal morphology between pre- and post-treatment groups and the controls. There were significant differences between pre-treatment and control groups in terms of progressive and non-progressive mobility. SPAG11A mRNA levels were significantly lower in the pre-treatment group than in healthy control subjects (p=0.007). p =0.007). There was no statistically significant difference in the expression of SPAG11A as well as semen parameters in the posttreatment group compared to the pre-treatment group. Conclusions: SPAG11A gene expression and semen parameters may be affected by varicocele. Whether varicocele treatment is an effective approach to reduce the adverse effect of this disease on SPAG11A expression and semen parameters needs further investigation.
- 1 January 2024
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 28 (3) , 405-409
Open AccessComparison of SPAG11A gene expression in infertile men with grade 1 and 2 varicocele before and after treatment
Objective: Sperm Associated Antigen 11A ( SPAG11A ) protein is a family of the epididymis-specific secretory proteins implicated in sperm maturation and function. Varicocele might cause pathophysiological difficulties in the testis and epididymis, with a harmful effect on the environment for spermatogenesis and sperm maturation. The aim of this study was to evaluate the expression level of the SPAG11A gene and sperm parameters in infertile men with grade 1 and 2 varicocele before and after treatment. Methods: Semen specimens were collected from 20 infertile men with varicocele pre-and post-treatment and 10 healthy volunteers. Semen analysis was conducted according to world health organization guidelines. Real time PCR (qRT-PCR) reaction was applied for determination of SPAG11A mRNA expression. Results: The results showed that there was a significant difference between the concentration and normal morphology between pre- and post-treatment groups and the controls. There were significant differences between pre-treatment and control groups in terms of progressive and non-progressive mobility. SPAG11A mRNA levels were significantly lower in the pre-treatment group than in healthy control subjects (p=0.007). p =0.007). There was no statistically significant difference in the expression of SPAG11A as well as semen parameters in the posttreatment group compared to the pre-treatment group. Conclusions: SPAG11A gene expression and semen parameters may be affected by varicocele. Whether varicocele treatment is an effective approach to reduce the adverse effect of this disease on SPAG11A expression and semen parameters needs further investigation.